摘要
目的探究达卡他韦和索非布韦治疗初治慢性丙型肝炎患者单核细胞亚群和表型的变化。方法选择2021年8月—2023年2月秦皇岛市第二医院初治慢性丙型肝炎患者共94例作为研究对象,均排除药物性、遗传性、自身免疫性肝病。以计算随机方式将患者分为常规治疗组、联合布韦组,各47例。常规治疗组以注射IFNα-2a进行治疗,联合布韦组以达卡他韦联合索非布韦进行治疗,比较两组TBil、TBA、ALT、AST、GGT、ALP水平,用流式细胞仪检测CD14^(+)CD16^(+)/CD14^(+)与CD14^(+)CD16^(-)/CD14^(+)表达,记录两组不良情况,并进行比较。结果在干预后,联合布韦组TBil、TBA水平较常规治疗组明显降低(P<0.05);与常规治疗组相比,联合布韦组干预后的ALT、AST水平明显降低(P<0.05);在干预后,与常规治疗组相比,联合布韦组GGT、ALP水平均明显降低(P<0.05);干预后,联合布韦组CD14^(+)CD16^(+)/CD14^(+)表达较常规治疗组降低,CD14^(+)CD16^(-)/CD14^(+)表达升高(P<0.05)。结论在初治慢性丙型肝炎中,应用达卡他韦和索非布韦能抑制肝细胞损伤,改善患者炎症及肝功能,通过对单核细胞的调控,提高患者免疫功能。
Objective To investigate the alterations in monocyte subsets and phenotypes in treatment-naive chronic hepatitis C patients undergoing daclatasvir and sofosbuvir therapy.Methods A total of 94 treatment-na ve chronic hepatitis C patients were enrolled in this study at our hospital from August 2021 to February 2023,excluding individuals with drug-induced,hereditary,or autoimmune liver diseases.The patients were randomly assigned to either a conventional therapy group or a combination therapy group,with 47 cases in each group.The conventional therapy group received IFNα-2a injections,while the combinaton therapy group was treated with a combination of daclatasvir and sofosbuvir.The levels of TBil,TBA,ALT,AST,GGT,ALP,γ-GT were compared between the two groups,and the expression of CD14^(+)CD16^(+)/CD14^(+)and CD14^(+)CD16^(-)/CD14^(+)was assessed using flow cytometry.Adverse events were monitoreded and compared between the two groups for further analysis.Results After treatment,the combination therapy group showed significantly lower levels of TBil and TBA compared to the conventional therapy group(P<0.05).Similarly,the levels of ALT and AST were significantly lower in the combination therapy group(P<0.05).Additionally,the levels of GGT,ALP andγ-GT were significantly reduced in the combination therapy group(P<0.05).Furthermore,the combination therapy group exhibited lower expression of CD14^(+)CD16^(+)/CD14^(+)and higher expression of CD14^(+)CD16^(-)/CD14^(+)compared to the conventional therapy group(P<0.05).Conclusion Combination therapy with daclatasvir and sofosbuvir in treatment-na ve chronic hepatitis C patients may alleviate hepatocyte damage,resulting in improvements in inflammatory and liver function.Additionally,this combination therapy can modulate monocytes,enhancing the immune response in these patients.
作者
刘雅光
胡连智
董一侠
LIU Ya-guang;HU Lian-zhi;DONG Yi-xia(Department of Pharmaceutical,Qinhuangdao Second Hospital,Hebei 066600,China;Department of General Surgery,Qinhuangdao Second Hospital,Hebei 066600,China;Shanhaiguan People′s Hospital of Qinhuangdao City,Hebei 066200,China)
出处
《肝脏》
2024年第4期440-443,共4页
Chinese Hepatology
基金
河北省卫计委2019年度医学科学研究课题计划(20191377)。
